-
Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand
•
Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its hemophilia B gene therapy, globally, citing “limited interest” from patients and physicians, according to reports in Nikkei Asia and Reuters. The move marks the U.S. pharma giant’s exit from virally delivered gene replacement treatments. Decision…
-
Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition. Financial Terms and Potential Impact on Astellas’ PipelineThe agreement allows…
-
Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases
•
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered into a licensing agreement with Genentech, a subsidiary of Swiss pharmaceutical giant Roche. The deal is aimed at developing intravenous genomic medicines for the treatment of specific neurodegenerative diseases. Sangamo has provided Genentech with an…
-
Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study
•
Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the Phase III AFFINE study for its gene therapy candidate, giroctocogene fitelparvovec, for the treatment of hemophilia A. With these results, Pfizer is now poised to prepare for regulatory submission for this one-time gene therapy, which…
